MARKET

BMY

BMY

Bristol-Myers Squibb Co
NYSE
44.03
-0.08
-0.18%
After Hours: 44.01 -0.02 -0.05% 19:59 05/17 EDT
OPEN
44.30
PREV CLOSE
44.11
HIGH
44.30
LOW
43.73
VOLUME
15.79M
TURNOVER
0
52 WEEK HIGH
67.35
52 WEEK LOW
43.33
MARKET CAP
89.25B
P/E (TTM)
-14.1996
1D
5D
1M
3M
1Y
5Y
Novo Nordisk, J&J lead R&D rankings in big pharma: report
Healthcare Novo Nordisk, J&J lead R&D rankings in big pharma: report in 2024 Innovation Index. Danish drugmaker has dethrone Pfizer from its two-year leadership in the index. Johnson & Johnson topped the 2024 Invention Index.
Seeking Alpha · 1d ago
May's 5 Dividend Growth Stocks With 5.49%+ Yields
Seeking Alpha · 2d ago
AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst
Benzinga · 2d ago
The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
NASDAQ · 2d ago
Do Wall Street Analysts Like Bristol-Myers Squibb Stock?
Barchart · 2d ago
Walmart Earnings & the State of the Consumer
NASDAQ · 3d ago
Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
NASDAQ · 3d ago
FDA Approves Expanded Use Of Bristol Myers Squibb's Breyanzi Cancer Cell Therapy For Previously Treated Follicular Lymphoma
The FDA granted accelerated approval to Bristol Myers Squibb Co’s Breyanzi for relapsed or refractory follicular lymphoma. The drug is a chimeric antigen receptor (CAR) T cell therapy for the disease. In April, the FDA said it would require boxed warnings for all CAR T-cell therapies.
Benzinga · 3d ago
More
About BMY
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.

Webull offers Bristol-Myers Squibb Co stock information, including NYSE: BMY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BMY stock methods without spending real money on the virtual paper trading platform.